Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 114
Filter
1.
Arq. neuropsiquiatr ; 80(2): 168-172, Feb. 2022. tab, graf
Article in English | LILACS | ID: biblio-1364368

ABSTRACT

ABSTRACT Background: Among the comorbidities that accompany multiple sclerosis (MS), restless legs syndrome (RLS) is one of the most common. Anxiety and depression are common psychological comorbidities that impact the quality of life of patients with MS (PwMS), as well as patients with RLS. Objective: To investigate the psychiatric burden of MS and RLS coexistence, we conducted a nationwide, multicenter and cross-sectional survey. Methods: Participants were assessed by using demographic and clinical parameters along with the Hamilton Anxiety and Hamilton Depression Scales (HAM-A and HAM-D). Results: Out of the 1,068 participants, 173 (16.2%) were found to have RLS [RLS(+)] and 895 (83.8%) did not [RLS(-)]. The mean scores for HAM-A and HAM-D were significantly higher among RLS(+) subjects than among RLS(-) subjects (p<0.001 for all variables). Conclusions: According to our data, the presence of RLS in PwMS may increase the occurrence of both anxiety and depression symptoms. Awareness and treatment of RLS in PwMS could possibly reduce the symptoms of psychiatric comorbidities originating from RLS.


RESUMO Antecedentes: Considerando-se as comorbidades que acompanham a esclerose múltipla (EM), a síndrome das pernas inquietas (SPI) é uma das mais comuns, e ansiedade e depressão são comorbidades psicológicas comuns que afetam a qualidade de vida de pacientes com EM, bem como de pacientes com SPI. Objetivo: Investigar a carga psiquiátrica da coexistência de EM e SPI por meio de uma pesquisa nacional, multicêntrica e transversal. Métodos: Os participantes foram avaliados por parâmetros demográficos e clínicos, além da versão turca das escalas de ansiedade e depressão de Hamilton (HAM-A e HAM-D). Resultados: Dos 1.068 participantes, 173 (16,2%) apresentaram SPI [SPI (+)] e 895 (83,8%) não [SPI (-)]. As pontuações médias no HAM-A e no HAM-D foram significativamente maiores em indivíduos com SPI (+) do que naqueles com SPI (-) (p <0,001 para todas as variáveis). Conclusões: De acordo com nossos dados, a presença de SPI na EM pode aumentar a ocorrência de sintomas de ansiedade e depressão. A conscientização e o tratamento da SPI na EM podem reduzir os sintomas de comorbidades psiquiátricas originadas da SPI.


Subject(s)
Humans , Restless Legs Syndrome/diagnosis , Restless Legs Syndrome/epidemiology , Multiple Sclerosis/complications , Multiple Sclerosis/epidemiology , Anxiety/epidemiology , Quality of Life , Cross-Sectional Studies , Depression
2.
Arq. neuropsiquiatr ; 79(8): 666-675, Aug. 2021. tab, graf
Article in English | LILACS | ID: biblio-1339239

ABSTRACT

ABSTRACT Background: Multiple sclerosis exhibits specific neuropathological phenomena driving to both global and regional brain atrophy. At the clinical level, the disease is related to functional decline in cognitive domains as the working memory, processing speed, and verbal fluency. However, the compromise of social-cognitive abilities has concentrated some interest in recent years despite the available evidence suggesting the risk of disorganization in social life. Recent studies have used the MiniSEA test to assess the compromise of social cognition and have found relevant relationships with memory and executive functions, as well as with the level of global and regional brain atrophy. Objective: The present article aimed to identify structural changes related to socio-cognitive performance in a sample of patients with relapsing-remitting multiple sclerosis. Methods: 68 relapsing-remitting multiple sclerosis Chilean patients and 50 healthy control subjects underwent MRI scans and neuropsychological evaluation including social-cognition tasks. Total brain, white matter, and gray matter volumes were estimated. Also, voxel-based morphometry was applied to evaluate regional structural changes. Results: Patients exhibited lower scores in all neuropsychological tests. Social cognition exhibited a significant decrease in this group mostly related to the declining social perception. Normalized brain volume and white matter volume were significantly decreased when compared to healthy subjects. The regional brain atrophy analysis showed that changes in the insular cortex and medial frontal cortices are significantly related to the variability of social-cognitive performance among patients. Conclusions: In the present study, social cognition was only correlated with the deterioration of verbal fluency, despite the fact that previous studies have reported its link with memory and executive functions. The identification of specific structural correlates supports the comprehension of this phenomenon as an independent source of cognitive disability in these patients.


RESUMEN Antecedentes: La esclerosis múltiple presenta fenómenos neuropatológicos específicos que conducen a la atrofia cerebral global y regional. A nivel clínico, la enfermedad está relacionada con el deterioro funcional de los dominios cognitivos como la memoria de trabajo, la velocidad de procesamiento y la fluidez verbal. Sin embargo, el compromiso de las habilidades socio-cognitivas ha concentrado cierto interés en los últimos años debido a la evidencia disponible que sugiere el riesgo de desorganización en la vida social. Estudios recientes han utilizado la prueba MiniSEA para evaluar el compromiso de la cognición social y han encontrado relaciones relevantes con la memoria y funciones ejecutiva, así como con el nivel de atrofia cerebral global y regional. Objetivo: El presente artículo tiene como objetivo identificar cambios estructurales relacionados con el rendimiento sociocognitivo en una muestra de pacientes con esclerosis múltiple recurrente-remitente. Métodos: 68 pacientes Chilenos con esclerosis múltiple recurrente-remitente y 50 sujetos de control sanos se sometieron a resonancias magnéticas y evaluación neuropsicológica, incluidas las tareas de cognición social. Se estimaron los volúmenes cerebrales totales, de materia blanca y materia gris. Además, se aplicó la morfometría basada en vóxel para evaluar los cambios estructurales regionales. Resultados: Los pacientes muestran puntuaciones más bajas en todas las pruebas neuropsicológicas. La cognición social exhibe una disminución significativa en este grupo principalmente relacionada con la disminución de la percepción social. El volumen normalizado del cerebro y el volumen de la materia blanca disminuyeron significativamente en comparación con los sujetos sanos. El análisis regional de atrofia cerebral mostró que los cambios en la corteza insular y la corteza frontal medial están significativamente relacionados con la variabilidad del rendimiento sociocognitivo entre los pacientes. Conclusiones: En el presente estudio, la cognición social sólo se correlacionó con el deterioro de la fluencia verbal, a pesar de que estudios previos han reportado su vinculación con la memoria y funciones ejecutivas. La identificación de correlatos estructurales específicos apoya la comprensión de este fenómeno como una fuente independiente de discapacidad cognitiva en estos pacientes.


Subject(s)
Humans , Multiple Sclerosis, Relapsing-Remitting , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Multiple Sclerosis/diagnostic imaging , Atrophy/pathology , Brain/pathology , Brain/diagnostic imaging , Magnetic Resonance Imaging , Cognition , Gray Matter/diagnostic imaging , Social Cognition , Neuropsychological Tests
3.
Arq. neuropsiquiatr ; 79(1): 44-50, Jan. 2021. tab, graf
Article in English | LILACS | ID: biblio-1153141

ABSTRACT

ABSTRACT Background: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary. Objective: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions. Methods: Cross-sectional study including 26 people with MS. Anxiety and/or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale. Results: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score. Conclusions: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.


RESUMO Introdução: A esclerose múltipla (EM) é uma doença imunomediada que afeta o sistema nervoso central. O impacto da doença transcende as funções físicas e se estende a comprometimento psicológico. Aproximadamente 50% das pessoas com EM desenvolvem sintomas depressivos e estes podem predizer o comprometimento das funções físicas. No entanto, a previsão de sintomas depressivos com base em medidas objetivas das funções físicas ainda é necessária. Objetivos: Comparar funções físicas entre pessoas com EM que apresentam ou não sintomas depressivos e identificar preditores de sintomas depressivos usando medidas objetivas de funções físicas. Métodos: Estudo transversal incluindo 26 pessoas com EM. A ansiedade e/ou sintomas depressivos foram avaliadas pelo Inventário de Depressão de Beck-II (Beck Depression Inventory - BDI-II) e pela Escala Hospitalar de Ansiedade e Depressão. Os resultados das funções físicas incluíram: teste de PEG de nove buracos, força muscular do joelho, controle de equilíbrio, teste Timed Up and Go (TUG) e teste da caminhada de seis minutos (TC6M). A fadiga percebida foi medida usando a escala de Borg. Resultados: A frequência de sintomas depressivos na amostra foi de 42%. O controle do equilíbrio durante tarefa desafiadora foi prejudicado em pessoas com EM e sintomas depressivos. O equilíbrio pode explicar 21-24% da variação nos sintomas depressivos. O TC6M e o TUG apresentaram tendência de significância que explica 16% da variância no escore do BDI-II. Conclusões: O comprometimento das funções físicas é potencial preditor de sintomas depressivos em pessoas com EM. São sugeridas intervenções de exercícios físicos visando melhora das funções físicas, juntamente com o tratamento médico convencional e dos sintomas depressivos.


Subject(s)
Humans , Depression/etiology , Multiple Sclerosis/complications , Time and Motion Studies , Cross-Sectional Studies , Postural Balance
4.
Braz. j. med. biol. res ; 54(3): e10428, 2021. tab, graf
Article in English | LILACS | ID: biblio-1153523

ABSTRACT

There is increasing evidence that neurofilament light chain (NF-L) can be considered as a biomarker for neuro-axonal damage. This polypeptide can be released into the cerebrospinal fluid (CSF) and the blood, where it can be quantified. The concentration of NF-L is elevated in patients with multiple sclerosis (MS) and psychiatric disorders. We aimed to investigate the NF-L levels in the CSF from treated MS patients and the relationship with depression or anxiety. The study involved three groups: control group (individuals without inflammation), the relapse-remitting multiple sclerosis (RRMS)-untreated group, and the RRMS-Fingo group (RRMS patients who were treated with fingolimod). MS disability was assessed by the Expanded Disability Status Scale, and depression and anxiety were evaluated by a neuropsychologist, using the Hospital Anxiety and Depression Scale, the Beck Depression Inventory-II, and the Beck Anxiety Inventory. Individual CSF samples were collected to measure NF-L levels. The results of the statistical analysis on levels of NF-L in the CSF of control subjects, RRMS-untreated patients, and RRMS-Fingo patients were significant. The relationship between depression and anxiety in RRMS-Fingo patients and NF-L levels was not statistically significant. In conclusion, MS events such as anxiety and depression appear to contribute to the onset of clinical relapses, subclinical cases, and neurodegeneration.


Subject(s)
Humans , Anxiety Disorders/etiology , Depression/etiology , Multiple Sclerosis/complications , Intermediate Filaments , Biomarkers , Neurofilament Proteins
5.
Rev. Hosp. Clin. Univ. Chile ; 32(1): 52-59, 2021.
Article in Spanish | LILACS | ID: biblio-1151924

ABSTRACT

Communication is an essential part of our social participation and the need to know how to evaluate and deal with its alterations is essential when working with people with neurological pathologies such as Multiple Sclerosis (MS). Purpose: to carry out a bibliographic review and group information related to communication problems, describing useful instruments for timely evaluation in the different areas involved. Material and method: bibliographic review related to the subject. Results: People with MS can face differents communication problems (aphasia, dysarthria or cognitive communicative disorder), it is important to have the characterization of these disorders and with tools that specifically carry out a pertinent evaluation with common language among experts. Conclusions: considering the importance of communication, its disorders as a consequence of MS and the forms of evaluation are a priority when intervening with this population. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Communication Disorders , Multiple Sclerosis/complications , Aphasia , Cognition Disorders , Dysarthria , Multiple Sclerosis/physiopathology
6.
Rev. méd. Maule ; 36(2): 15-23, dic. 2020. tab
Article in Spanish | LILACS | ID: biblio-1344586

ABSTRACT

INTRODUCTION: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, which occurs in up to 85% of cases as relapsing remitting (RR), with episodes of neurological dysfunction partially forwarded. Its treatment in Chile is financially protected by the Explicit Health Guarantees (GES) and Law 20,850 on high-cost diseases. The Regional Hospital of Talca (HRT) has 25 patients benefiting from Law 20,850 in treatment with second-line biologic therapy. Adverse reactions (RAM) to the use of these drugs have been described and to date there are no case reports or studies of significant adverse events in Chile. Objectives: To present the experience of the use of biologic therapy in EMRR in HRT, in relation to adverse events. METHODS: A review of the current guidelines in Chile for the treatment of relapsing-remitting multiple sclerosis and the protocol of law 20,850 was carried out, the clinical records of 25 patients benefiting from the law in the HRT were reviewed, with emphasis on the adverse events presented before First and second line therapies and the con sequences of these events on the continuity of therapy. RESULTS: Half of the patients who started their treatment with first-line drugs had adverse effects, of which 28% involved a change in therapy, the remaining changed from therapy due to failure to treatment. Of the 26 patients included in the sample, 24 are currently using second-line drugs. The profile of adverse effects should be a variable to consider when indicating a therapy for MS.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , Chile , Interferon-beta/administration & dosage , Interferon-beta/adverse effects , Practice Guidelines as Topic , Glatiramer Acetate/adverse effects , Immunosuppressive Agents , Multiple Sclerosis/complications
7.
Arq. neuropsiquiatr ; 78(11): 708-712, Nov. 2020. tab
Article in English | LILACS | ID: biblio-1142357

ABSTRACT

ABSTRACT Background: Restless legs syndrome (RLS) is one of the most common and burdensome sleep disorders in the course of multiple sclerosis (MS). Objective: To evaluate common MS-related symptoms and consequences between groups with and without RLS and further assess the association of quality of life determinants with RLS symptom severity. Methods: According to their RLS status, 46 relapsing-remitting MS patients were divided into MS-RLS+ (n=19) and MS-RLS- groups (n=27). Specific questionnaires were administered to assess the patients' health-related quality of life (HRQoL), fatigue levels, sleep quality, daily sleepiness, anxiety, and depression symptoms. Functional capacity was examined using the Expanded Disability Status Scale (EDSS). Results: The prevalence of RLS was 41.3%. Compared to the MS-RLS- group, those with RLS had higher EDSS scores, more cranial and spinal lesions, longer disease duration, and were older. In the MS-RLS+ group, symptom severity scores were positively correlated with higher anxiety and poorer sleep quality. The symptom severity score was negatively correlated with mental HRQoL and pain scores. Conclusion: In conclusion, the findings of the current study indicate the negative impact of RLS on functional capacity, anxiety, sleep quality, and mental HRQoL of MS patients. Further studies using more accurate diagnostic strategies for identifying RLS and other sleep disorders are necessary to clarify the association of MS with RLS and explore relevant clinical implications.


RESUMEN Antecedentes: El síndrome de piernas inquietas (SPI) es uno de los trastornos del sueño más comunes y onerosos en el curso de la esclerosis múltiple (EM). Objetivo: El objetivo de este estudio fue evaluar los síntomas y las consecuencias comunes asociados con la EM entre los grupos con y sin SPI y evaluar aún más la asociación de los determinantes de la calidad de vida con la gravedad de los síntomas del SPI. Métodos: De acuerdo con su estado de SPI, 46 pacientes con EM recurrente-remitente se dividieron en los grupos EM-SPI+ (n=19) y EM-SPI- (n=27). Se utilizaron cuestionarios específicos para evaluar la calidad de vida relacionada con la salud (CVRS), los niveles de fatiga, la calidad del sueño, la somnolencia diaria, la ansiedad y los síntomas de depresión de los pacientes. La capacidad funcional se examinó mediante la escala ampliada del estado de discapacidad (Expanded Disability Status Scale — EDSS). Resultados: La prevalencia de SPI fue del 41,3%. Em comparación com el grupo EM-SPI-, aquellos com SPI tenían púntuaciones más altas em la EDSS, más lesiones craneales y espinales, mayor duración de la enfermedad y eran mayores. Los puntajes de gravedad de los síntomas em el grupo EM-SPI+ se correlacionaron positivamente con una mayor ansiedad y una peor calidad del sueño. Se observaron correlaciones negativas entre la puntuación de gravedad de los síntomas y la CVRS mental y los puntajes de dolor. Conclusiones: En conclusión, el estudio actual indica el impacto negativo del SPI en la discapacidad funcional, la ansiedad, la calidad del sueño y la CVRS mental de los pacientes con EM. Se necesitan más estudios que utilicen estrategias de diagnóstico más precisas para identificar el SPI y otros trastornos del sueño para aclarar la asociación de la EM con el SPI y para explorar implicaciones clínicas relevantes.


Subject(s)
Humans , Restless Legs Syndrome/epidemiology , Sleep Wake Disorders/etiology , Sleep Wake Disorders/epidemiology , Multiple Sclerosis/complications , Anxiety/etiology , Anxiety/epidemiology , Quality of Life , Cross-Sectional Studies , Surveys and Questionnaires
8.
Arq. neuropsiquiatr ; 77(7): 521-524, July 2019. graf
Article in English | LILACS | ID: biblio-1011368

ABSTRACT

ABSTRACT Neuropsychiatric disorders in multiple sclerosis have been known since the original clinicopathological description by Charcot in the late nineteenth century. Charcot, in the last decades of his life, became involved in the field of neuropsychiatry. This produced a battle between rival schools in the era that still echoes to this day. Charcot's intuition, including the line of thought of Babinski, one of his most famous disciples, was that there was a connection between mood disorders and many of the diseases of the nervous system. Medicine's concern with establishing a relationship between mood disorders and disease stems from the ancient and middle ages with references found in the Hippocratic doctrine. However, it was only in the second half of the nineteenth and early twentieth century, with Charcot's discoveries, that this discussion was established in a structured way, laying the foundations of neuropsychiatry.


RESUMO Os distúrbios neuropsiquiátricos na esclerose múltipla são conhecidos desde a descrição clínico-patológica original de Charcot no final do século XIX. Charcot nas últimas décadas de sua vida se envolveu no campo da neuropsiquiatria. Isso produziu uma batalha de escolas rivais na época que ainda ecoa até hoje. A intuição de Charcot, incluindo a linha de pensamento de Babinski, um de seus discípulos mais famosos, foi a teoria correta da conexão entre os transtornos do humor e muitas das doenças do sistema nervoso. A preocupação da Medicina em estabelecer uma relação entre transtornos do humor e doenças vem das idades antiga e média, com referências encontradas na doutrina hipocrática. No entanto, foi apenas na segunda metade do século XIX e início do século XX que, com as descobertas de Charcot essa discussão foi realizada de maneira estruturada, estabelecendo os fundamentos da neuropsiquiatria.


Subject(s)
Humans , History, 19th Century , History, 20th Century , Mood Disorders/diagnosis , Neuropsychiatry/history , Multiple Sclerosis/history , Neurology/history , Mood Disorders/etiology , Mood Disorders/history , Malaria/history , Malaria/therapy , Multiple Sclerosis/complications
9.
Clinics ; 74: e713, 2019. tab, graf
Article in English | LILACS | ID: biblio-989633

ABSTRACT

OBJECTIVES: To assess the prevalence and interrelationship between lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis (MS). METHODS: In a cross-sectional study, we evaluated 41 men (mean age 41.1±9.9 years) with MS from February 2011 to March 2013, who were invited to participate irrespective of the presence of lower urinary tract symptoms or sexual dysfunction. Neurological impairment was assessed with the Expanded Disability Status Scale; lower urinary tract symptoms were evaluated with the International Continence Society male short-form questionnaire, and sexual dysfunction was evaluated with the International Index of Erectile Function. All patients underwent transabdominal urinary tract sonography and urine culture. RESULTS: The mean disease duration was 10.5±7.3 years. Neurological evaluation showed a median Expanded Disability Status Scale score of 3 [2-6]. The median International Continence Society male short-form questionnaire score was 17 [10-25]. The median International Index of Erectile Function score was 29 [15-46]. Twenty-nine patients (74.4%) had sexual dysfunction as defined by an International Index of Erectile Function score <45. Voiding dysfunction and sexual dysfunction increased with the degree of neurological impairment (r=0.02 [0.02 to 0.36] p=0.03 and r=-0.41 [-0.65 to -0.11] p=0.008, respectively). Lower urinary tract symptoms and sexual dysfunction also displayed a significant correlation (r=-0.31 [-0.56 to -0.01] p=0.04). CONCLUSIONS: Most male patients with MS have lower urinary tract symptoms and sexual dysfunction. The severity of the neurological disease is a predictive factor for the occurrence of voiding and sexual dysfunctions.


Subject(s)
Humans , Male , Adult , Middle Aged , Aged , Young Adult , Sexual Dysfunction, Physiological/epidemiology , Lower Urinary Tract Symptoms/epidemiology , Multiple Sclerosis/epidemiology , Quality of Life , Sexual Dysfunction, Physiological/complications , Sexual Dysfunction, Physiological/diagnosis , Severity of Illness Index , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Surveys and Questionnaires , Urinary Bladder, Overactive/complications , Lower Urinary Tract Symptoms/complications , Lower Urinary Tract Symptoms/diagnosis , Erectile Dysfunction/complications , Multiple Sclerosis/complications , Multiple Sclerosis/diagnosis
10.
Arq. neuropsiquiatr ; 76(7): 430-435, July 2018. tab, graf
Article in English | LILACS | ID: biblio-950561

ABSTRACT

ABSTRACT Chronic neurological disorders generate disabilities affecting multiple aspects of life, including sexuality. Objective To describe the presence of sexual dysfunction and comorbidities in a population with chronic neurological disorders. To analyze the relationship between disability and sexual dysfunction. Methods A cross-sectional case-control study was carried out. Patients with amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), and stroke of at least one year since the onset of symptoms were included, and compared with controls with no neurological disease, matched by age and sex. Results We included 71 participants: 29 controls, with a mean age of 49.4 years, and 42 patients with a mean age of 53.8 years. Sexual dysfunction was present in 22.5% of the controls and 77.5% of the patients. A statistically significant relationship between sexual dysfunction and disability was found in the logistic regression analysis (OR = 20.38, 95%CI: 2.5 -165.86). Conclusions Disability proved to be the main variable related to the presence of sexual dysfunction. Patients with ALS had the worst rates of sexual dysfunction. Patients with MS were similar to the control group. As for the PD group, no patient had normal sexuality. Finally, in stroke patients, the presence of comorbidities and their treatment may have negatively influenced sexuality. These findings showed that patients with chronic neurological diseases have sexual dysfunction and underscore the need for neurologists to know and address this problem.


RESUMO Las enfermedades neurológicas crónicas generan discapacidad afectando múltiples aspectos de la vida, incluida la sexual. Objetivo Describir en una población con enfermedades neurológicas crónicas la presencia de disfunción sexual y posibles comorbilidades acompañantes. Analizar la relación entre discapacidad y disfunción sexual. Métodos Se realizó un estudio transversal de tipo casos y controles. Se incluyeron pacientes con Esclerosis Lateral Amiotrófica (ELA), Esclerosis Múltiple (EM), enfermedad de Parkinson (EP) y secuelados por enfermedad cerebrovascular (sACV) de al menos un año de evolución, controlando con sujetos sin enfermedad neurológica pareados por edad y sexo. Resultados Se incluyeron 71 sujetos: 29 controles, con una edad media 49,4 años y 42 casos con una edad media de 53,8 años. Presentaron disfunción sexual el 22,5% de los controles y el 77,5% de los casos. En el análisis por regresión logística se encontró una relación estadísticamente significativamente entre disfunción sexual y discapacidad. (OR = 20.38, IC95%: 2.5-165.86). Conclusiones La discapacidad demostró ser la principal variable relacionada con la presencia de disfunción sexual. Los enfermos con ELA fueron los que peores índices de disfunción sexual presentaron. Los pacientes con EM se comportaron de forma similar al grupo control. En cuanto al grupo de EP todos los pacientes tuvieron algún trastorno en su sexualidad. Por último, en sACV la presencia de comorbilidades y su tratamiento podrían influir negativamente en la sexualidad. Estos hallazgos evidencian que la disfunción sexual está presente en los pacientes con enfermedades neurológicas crónicas y confirma la necesidad de conocer este problema por parte de los neurólogos.


Subject(s)
Humans , Male , Female , Middle Aged , Parkinson Disease/complications , Stroke/complications , Amyotrophic Lateral Sclerosis/complications , Multiple Sclerosis/complications , Nervous System Diseases/complications , Severity of Illness Index , Case-Control Studies , Chronic Disease , Cross-Sectional Studies
11.
Arq. neuropsiquiatr ; 75(10): 687-691, Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-888260

ABSTRACT

ABSTRACT Autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients with inflammatory central nervous system disorders including isolated optic neuritis (ON). We compared our MOG-IgG ON patients with multiple sclerosis (MS) patients presenting with ON. Methods and results: Among the total of 38 patients with optic neuropathies, six patients with isolated ON were MOG-IgG positive and eight patients with ON fulfilled the diagnostic criteria for MS. All MS patients were negative for MOG-IgG using a cell-based assay. When compared with the MS group, the MOG-IgG patients were older (mean 47 years), more frequently male (ratio 2:1) and had a higher frequency of bilateral and/or recurrent ON. The brain magnetic resonance imaging of all MOG-IgG positive patients was normal or had only unspecific white matter T2 lesions. Conclusion: These findings suggest that MOG-IgG is a biomarker of an inflammatory demyelinating CNS disease distinct from MS.


RESUMO Autoanticorpos contra a glicoproteína da mielina do oligodendrócito (MOG-IgG) têm sido descritos em pacientes com neurite óptica (NO) isolada, entre outras doenças inflamatórias do sistema nervoso central. Comparamos os nossos pacientes com NO MOG-IgG positivos com pacientes com NO associada a esclerose múltipla (EM). Materias e métodos: De um total de 38 pacientes com neuropatia óptica, seis foram MOG-IgG positivos e oito preencheram critérios diagnósticos para EM. Todos os pacientes com EM foram negativos para MOG-IgG (ensaio baseado em células). Quando comparados ao grupo com EM, os pacientes MOG-IgG positivos apresentam idade mais avançada (mediana de 47 anos) e tiveram uma frequência maior de NO bilateral e/ou recorrente. Houve predomínio masculino (relação 2:1). A ressonância magnética de encéfalo de todos os pacientes MOG-IgG positivos foi normal ou demonstrou apenas lesões inespecíficas em T2. Conclusão: Nossos achados sugerem que o MOG-IgG é um biomarcador de doença desmielinizante diferente da EM.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Autoantibodies/blood , Biomarkers/blood , Optic Neuritis/blood , Myelin-Oligodendrocyte Glycoprotein/immunology , Multiple Sclerosis/blood , Autoantibodies/immunology , Magnetic Resonance Imaging , Optic Neuritis/complications , Myelin-Oligodendrocyte Glycoprotein/blood , Multiple Sclerosis/complications
13.
Rev. bras. oftalmol ; 76(3): 133-137, maio-jun. 2017. tab
Article in Portuguese | LILACS | ID: biblio-899054

ABSTRACT

RESUMO Objetivos: Determinar a freqüência e as características das alterações em exame oftalmológico, em exame de Tomografia de coerência óptica (OCT) do nervo e mácula e Campimetria em pacientes com Escrelose Multipla(EM). Métodos: Foram examinados 60 olhos sendo 30 de pacientes com o diagnóstico de EM e 30 de pacientes controles, atendidos no Hospital de Base do Distrito Federal. Os pacientes foram avaliados quanto aos parâmetros: características e alterações do exame oftalmológico, do OCT do nervo e da macula e Campimetria. Resultados: Os pacientes com EM apresentaram piores resultados em todos os parâmetros avaliados. No exame de campo visual Foram encontradas perdas localizadas em 50%. Em relação ao OCT de nervo óptico foi observado redução da camada de fibras nervosas em quadrantes temporal (p=0,0251) e inferior (p=0,0041), o OCT de mácula revelou diminuição da CFN principalmente nos quadrantes nasal interno (p=0,0002) e externo (p=0,0016),inferior interno (p=0,0007) e superior externo (p=0,0108) e interno (p=0,0046). Os pacientes com menores valores de espessura macular também tiveram piores resultados no campo visual (p=0,0001). Conclusão: Este estudo demonstrou que a EM é uma doença capaz de ocasionar alterações nos exames de OCT e Campo visual mesmo na ausência de sintomas visuais relatados pelos pacientes. A realização de exames como campo visual e de OCT de macula e nervo podem ser uma ferramenta útil para estimar o comprometimento pela doença e auxiliar no seguimento desses pacientes.


ABSTRACT Objectives: To determine the frequency and characteristics of alterations in ophthalmologic examinations of optic nerve and macula coherence tomography (OCT), and Campimetry in multiple sclerosis (MS) patients. Methods: Sixty eyes were examined, 30 of which were diagnosed with MS and 30 of the control patients, all attended at the General Hospital of the Federal District of Brazil. The patients were evaluated regarding the parameters: characteristics and alterations of the ophthalmological examination, OCT of the nerve and macula and Campimetry. Results: Patients with MS presented worse results in all parameters evaluated. On visual field examination localized losses were found in 50% of the cases . In relation to OCT of the optic nerve it was observed a reduction of the nerve fiber layer in temporal quadrants (p = 0.0251) and lower (p = 0.0041). The macular OCT revealed a decrease in the CFN, mainly in the internal nasal quadrants (p = 0.0002) and external (p = 0.0016), internal inferior (p = 0.0007) and external superior (p = 0.0108) plus internal (p = 0.0046). Patients with lower values of macular thickness also had worse results in the visual field (p = 0.0001). Conclusion: This study demonstrated that MS is a disease capable of causing changes in OCT and visual field tests even in the absence of visual symptoms reported by patients. Examinations such as visual field and OCT of macula and nerve can be a useful tool to estimate the damage by the disease and to assist in the follow-up of these patients


Subject(s)
Humans , Male , Female , Adult , Vision Disorders/diagnosis , Tomography, Optical Coherence , Visual Field Tests , Multiple Sclerosis/complications , Optic Nerve/diagnostic imaging , Vision Disorders/etiology , Case-Control Studies , Epidemiology, Descriptive , Cross-Sectional Studies , Diagnostic Techniques, Ophthalmological , Macula Lutea/diagnostic imaging , Nerve Fibers/pathology
14.
Arq. neuropsiquiatr ; 75(6): 345-348, June 2017. tab, graf
Article in English | LILACS | ID: biblio-838926

ABSTRACT

ABSTRACT We studied multiple sclerosis (MS) patients with the HLA-DQB1*06:02 allele and compared them with MS patients who did not carry the HLA-DQB1*06:02 allele. We analyzed clinical and neurophysiological criteria for narcolepsy in six MS patients with HLA-DQB1*06:02, compared with 12 MS patients who were HLA-DQB1*06:02 non-carriers. Only two patients with HLA-DQB1*06:02 allele scored higher than 10 on the Epworth Sleepiness Scale. Polysomnography recording parameters and the multiple sleep latency test showed an absence of narcolepsy in the study group. Our study suggested no significant correlation between narcolepsy, MS and HLA-DQB1*06:02. The HLA-DQB1*06:02 allele alone was not sufficient to cause MS patients to develop narcolepsy.


RESUMO Pacientes com esclerose múltipla (EM) portadores do alelo HLA-DQB1*06:02 foram estudados e comparados com pacientes com EM mas que não são portadores do alelo HLA-DQB1*06:02. Os critérios clínicos e neurofisiológicos para narcolepsia foram analisados em pacientes com EM sendo 6 pacientes com o HLA-DQB1*06:02 comparados a 12 pacientes sem o HLA-DQB1*06:02. Somente 2 pacientes com EM e HLA-DQB1*06:02 tiveram escore maior que 10 na escala “Epworth Sleepiness Scale”. Os parâmetros da polissonografia e o teste de múltiplas latências do sono mostraram ausência de narcolepsia no grupo estudo. Nosso estudo não sugere correlações significantes entre narcolepsia, EM e HLA-DQB1*06:02. Somente o HLA-DQB1*06:02 não foi suficiente para desenvolver narcolepsia em pacientes com EM.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , HLA-DQ beta-Chains/genetics , Multiple Sclerosis/complications , Narcolepsy/etiology , Polysomnography , Gene Frequency , Genotype , Multiple Sclerosis/genetics , Narcolepsy/diagnosis , Narcolepsy/genetics
15.
Arq. neuropsiquiatr ; 75(6): 394-401, June 2017. tab
Article in English | LILACS | ID: biblio-838919

ABSTRACT

ABSTRACT The existence of a benign multiple sclerosis (BMS) form is a controversial subject. Recent studies of these patients reveal different levels of cognitive impairment, despite the apparent preservation of motor function. The objective of this study was to review and analyze a number of publications that discuss the general aspects of this disease form, such as the definition criteria, prevalence, and clinical and neuroimaging markers. A systematic review of published data on BMS up to October 2015 was performed. Thirty-one published articles were analyzed. The estimated frequency of BMS varied between 6% and 73%. Cognitive impairment was recognized as affecting 17% to 47% of the subjects and presented significant correlation with neuroimaging, such as brain atrophy, increased lesion volume in T2 magnetic resonance assay, and regional grey matter atrophy. The current criteria overestimated the frequency of BMS and, for that reason, this highlights the importance of validating the diagnostic methods practiced.


RESUMO A existência real de uma forma benigna da esclerose múltipla (EMB) é um tema controverso. Ampliar o número de publicações que abordam os aspectos gerais do subtipo da doença, tais como os critérios de definição utilizados, análise de prevalência e da presença de marcadores clínicos e de neuroimagem. Foi realizada uma revisão sistemática dos dados publicados até outubro de 2015, relativa à EMB. Os dados encontrados foram dicotomizados em gráficos e, posteriormente, analisados. Foram analisados 31 artigos publicados. A frequência estimada EMB oscila entre 6% a 73%. O comprometimento cognitivo foi reconhecido em 17–47% dos sujeitos, apresentando correlação significativa com os aspectos de neuroimagem, como a atrofia cerebral global, aumento do volume lesional em T2 e atrofia regional da substância cinzenta. Os critérios atualmente utilizados superestimam a freqüência de EMB, e, por essa razão, destaca-se a importância da validação dos métodos de diagnóstico praticados.


Subject(s)
Humans , Cognition Disorders/etiology , Cognition Disorders/pathology , Cognition Disorders/diagnostic imaging , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Multiple Sclerosis/diagnostic imaging , Neuroimaging
16.
Rev. bras. reumatol ; 57(3): 224-228, May-June 2017. tab
Article in English | LILACS | ID: biblio-899417

ABSTRACT

ABSTRACT Introduction: Multiple sclerosis (MS) and neuromyelitis optica (NMO) are demyelinating diseases of the central nervous system. Autoimmunity in patients with demyelinating disease and in their families has been broadly investigated and discussed. Recent studies show a higher incidence of rheumatic autoimmune diseases among adult patients with MS or NMO and their families, but there are no studies in the pediatric population. Objective: To evaluate an association of MS and NMO with autoimmune rheumatic diseases in pediatric patients. Method: 22 patients younger than 21 years old with MS or NMO diagnosed before the age of 18 years were evaluated regarding epidemiological data, clinical presentation, association with autoimmune diseases, family history of autoimmune diseases, laboratory findings, imaging studies and presence of auto-antibodies. Results: Among the patients studied, there was a prevalence of females (68.1%). The mean age of symptoms onset was 8 years and 9 months and the mean current age was 16 years and 4 months. Two patients (9%) had a history of associated autoimmune rheumatic disease: one case of juvenile dermatomyositis in a patient with NMO and another of systemic lupus erythematosus in a patient with MS. Three patients (13%) had a family history of autoimmunity in first-degree relatives. Antinuclear antibody was found positive in 80% of patients with NMO and 52% of patients with MS. About 15% of antinuclear antibody-positive patients were diagnosed with rheumatologic autoimmune diseases. Conclusion: Among patients with demyelinating diseases diagnosed in childhood included in this study there was a high frequency of antinuclear antibody positivity but a lower association with rheumatologic autoimmune diseases than that observed in studies conducted in adults.


RESUMO Introdução: Esclerose múltipla (EM) e neuromielite óptica (NMO) são doenças desmielinizantes do sistema nervoso central. A autoimunidade entre pacientes com doenças desmielinizantes e seus parentes tem sido amplamente investigada e discutida. Estudos recentes demonstram maior incidência de doenças reumáticas autoimunes entre pacientes adultos com EM e NMO e seus parentes, mas não há estudos na população pediátrica. Objetivo: Avaliar a associação de EM e NMO com doenças reumáticas autoimunes em pacientes pediátricos. Método: Foram incluídos 22 pacientes menores de 21 anos com diagnóstico de EM ou NMO antes dos 18 anos e avaliados dados epidemiológicos, clínicos, associação com doenças autoimunes, história familiar de doenças autoimunes, exames laboratoriais, exames de imagem e presença de autoanticorpos. Resultados: Entre os pacientes estudados, houve prevalência do sexo feminino (68,1%). A média de idade de início dos sintomas foi de oito anos e nove meses e a média de idade dos pacientes na avaliação foi 16 anos e quatro meses. Dois pacientes (9%) apresentaram doença reumática autoimune associada, um caso de dermatomiosite juvenil em paciente com NMO e outro de lúpus eritematoso sistêmico juvenil em paciente com EM. Três pacientes (13%) apresentaram história familiar de autoimunidade em parentes de primeiro grau. Anticorpo antinuclear (ANA) positivo foi encontrado em 80% dos pacientes com NMO e em 52% dos pacientes com EM. Cerca de 15% dos pacientes com ANA positivo apresentaram diagnóstico definitivo de doença autoimune reumática associada. Conclusão: Entre os pacientes com doenças desmielinizantes diagnosticadas durante a infância incluídos nesta pesquisa houve uma alta frequência de ANA positivo, mas uma menor taxa de associação com doenças reumáticas autoimunes do que a encontrada em trabalhos conduzidos em adultos.


Subject(s)
Humans , Male , Female , Child , Adolescent , Autoimmune Diseases/etiology , Rheumatic Diseases/etiology , Neuromyelitis Optica/complications , Multiple Sclerosis/complications , Autoimmune Diseases , Autoimmune Diseases/epidemiology , Rheumatic Diseases/epidemiology , Prevalence , Retrospective Studies , Risk Factors
17.
Rev. bras. neurol ; 53(1): 38-41, jan.-mar. 2017. ilus, tab
Article in Portuguese | LILACS | ID: biblio-832764

ABSTRACT

A forma pseudotumoral de esclerose múltipla é extremamente rara e possui uma grande variedade de diagnósticos diferenciais, o que a torna um desafio na prática neurológica. Neste artigo, apresentamos um caso desta manifestação incomum de esclerose múltipla, que foi avaliado em uma clínica especializada no Rio de Janeiro. O caso é de um individuo do sexo masculino de 21 anos que apresentou apenas crises convulsivas. Apresentou curso benigno da doença.


Pseudotumoral forms of multiple sclerosis are very and have a great variety of differential diagnosis, which poses it as a great challenge in neurological practice. In this paper, we report one case of this uncommon manifestation of multiple sclerosis, which was assessed in a specialized clinic in Rio de Janeiro. The case is a 21 year old male patient that had only seizures. He presented a benign course of the disease.


Subject(s)
Humans , Male , Young Adult , Pseudotumor Cerebri/diagnosis , Multiple Sclerosis/complications , Multiple Sclerosis/diagnosis , Multiple Sclerosis/epidemiology , Seizures/etiology , Skull/diagnostic imaging , Review Literature as Topic , Tomography, X-Ray Computed/statistics & numerical data , Diagnosis, Differential
18.
Arq. neuropsiquiatr ; 75(3): 139-141, Mar. 2017. tab, graf
Article in English | LILACS | ID: biblio-838875

ABSTRACT

ABSTRACT Patients with malignant multiple sclerosis (MMS) reach a significant level of disability within a short period of time (Expanded Disability Status Scale score of 6 within five years). The clinical profile and progression of the disease were analyzed in a Brazilian cohort of 293 patients. Twenty-five (8,53%) patients were found to have MMS and were compared with the remaining 268 (91,47%). Women, non-white patients, older age at disease onset, shorter intervals between the first attacks, and more attacks in the first two years of the disease were all more common in the MMS group. These findings could serve as prognostic factors when making therapeutic decisions.


RESUMO Os doentes com esclerose múltipla maligna (EMM) atingem um nível significativo de incapacidade dentro de um curto período de tempo (EDSS 6 em até 5 anos desde primeiro sintoma/sinal da doença). O perfil clínico e progressão da doença foram analisados em uma coorte brasileira de 293 pacientes. Vinte e cinco (8,53%) pacientes foram encontrados com EMM e foram comparados com os restantes 268 (91,47%). Mulheres, pacientes não-brancos, idade mais avançada no início da doença, intervalos mais curtos entre os primeiros ataques e, mais ataques nos dois primeiros anos da doença, foram mais comuns no grupo com EMM. Estes achados podem servir como fatores prognósticos na tomada de decisão terapêutica.


Subject(s)
Humans , Female , Adult , Middle Aged , Multiple Sclerosis/physiopathology , Prognosis , Severity of Illness Index , Retrospective Studies , Disease Progression , Disability Evaluation , Multiple Sclerosis/complications
19.
Arq. neuropsiquiatr ; 75(1): 3-8, Jan. 2017. tab, graf
Article in English | LILACS | ID: biblio-838849

ABSTRACT

ABSTRACT Objective: Vitamin D has taken center stage in research and treatment of multiple sclerosis (MS). The objective of the present study was to assess the serum vitamin D levels of a large population of patients with MS and controls living in a restricted tropical area. Methods: Data from 535 patients with MS and 350 control subjects were obtained from 14 cities around the Tropic of Capricorn. Results: The mean serum 25-OH vitamin D level was 26.07 ± 10.27 ng/mL for the control subjects, and 28.03 ± 12.19 ng/mL for patients with MS. No correlation was observed between vitamin D levels and the disability of patients over the disease duration. Conclusion: At least for the region around the Tropic of Capricorn, serum levels of vitamin D typically are within the range of 20 to 30 ng/mL for controls and patients with MS.


RESUMO Objetivo: Vitamina D assumiu um papel central na pesquisa e tratamento da esclerose múltipla (EM). O objetivo deste estudo foi avaliar os níveis séricos de vitamina D de pacientes com EM e controles que residem em uma área tropical. Métodos: Foram analisados dados de 535 pacientes com EM e 350 indivíduos controle em 14 cidades próximas ao Trópico de Capricórnio. Resultados: O valor médio da determinação de 25-OH vitamina D foi 26,07 ± 10,27 ng/mL para controles e 28,03 ± 12,19 ng/mL para pacientes com EM. Não houve correlação entre os níveis de vitamina D e o grau de incapacidade ao longo da duração da doença. Conclusão: Pelo menos na região que cerca o Trópico de Capricórnio, os níveis séricos de vitamina D estão entre valores de 20 a 30 ng/mL tanto para controles quanto para pacientes com EM.


Subject(s)
Humans , Male , Female , Adult , Vitamin D/blood , Vitamin D Deficiency/blood , Multiple Sclerosis/blood , Vitamin D Deficiency/complications , Brazil , Case-Control Studies , Disease Progression , Disability Evaluation , Geography, Medical , Multiple Sclerosis/complications
20.
Braz. J. Pharm. Sci. (Online) ; 53(1): e16132, 2017. tab, graf
Article in English | LILACS | ID: biblio-839461

ABSTRACT

Abstract To determine the association between factors and adherence to immunomodulator treatment in people with multiple sclerosis treated in reference centers. Cross-sectional study conducted with 188 people who used immunomodulators in three reference centers in Ceará from March to July 2012. Adherence was assessed using the Moriskscale and factors were assessed using a questionnaire addressing socioeconomic and personal characteristics, the disease, the use of immunomodulator and educational activities. The determination of the association was expressed in crude and adjusted odds ratio with a 95% confidence interval. Adherence rate was 46% and after the logistic regression model the adherence to immunomodulator treatment was positively associated with the following factors: age 18-38 years, time of diagnosis and treatment between 6 and 24 months, 0-3.5 score in the Expanded Disability Status Scale, perception of treatment benefits, intrinsic and extrinsic motivation, phone contact with the doctor and not missing the return visit. This study is important because it allowed to determine the association between factors and adherence to immunomodulator treatment in multiple sclerosis, contributing to prevention and control actions.


Subject(s)
Humans , Male , Female , Adult , Medication Adherence/statistics & numerical data , Immunologic Factors/analysis , Multiple Sclerosis/complications , Multiple Sclerosis/prevention & control , Patients/statistics & numerical data , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL